# Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure

François Bughin, Isabelle Jaussent, Bronia Ayoub, Sylvain Aguilhon, Nicolas Chapet, Sonia Soltani, Jacques Mercier, Yves Dauvilliers, François Roubille

<figure><img src="image_1.png" /></figure>

► To cite this version:

François Bughin, Isabelle Jaussent, Bronia Ayoub, Sylvain Aguilhon, Nicolas Chapet, et al. Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure. Journal of Clinical Medicine, 2021, 10 (22), pp.5387. 10.3390/jcm10225387. hal-03453647v2

HAL Id: hal-03453647

https://hal.science/hal-03453647v2

Submitted on 12 Apr 2022

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
Article

# Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure

François Bughin<fnref n="1" /> ID, Isabelle Jaussent<fnref n="2" />, Bronia Ayoub<fnref n="1" />, Sylvain Aguilhon<fnref n="3" />, Nicolas Chapet<fnref n="4" />, Sonia Soltani<fnref n="3" />, Jacques Mercier<fnref n="1" />, Yves Dauvilliers<fnref n="5" /> and François Roubille<fnref n="1" />,<fnref n="3" />,* ID

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Bughin, F.; Jaussent, I.; Ayoub, B.; Aguilhon, S.; Chapet, N.; Soltani, S.; Mercier, J.; Dauvilliers, Y.; Roubille, F. Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure. *J. Clin. Med.* **2021**, *10*, 5387. https://doi.org/10.3390/jcm10225387

Academic Editors: Feola Mauro and
Emmanuel Andrès

Received: 12 October 2021

Accepted: 16 November 2021

Published: 18 November 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Abstract:** Sleep disturbances are frequent among patients with heart failure (HF). We hypothesized that self-reported sleep disturbances are associated with a poor prognosis in patients with HF. A longitudinal study of 119 patients with HF was carried out to assess the association between sleep disturbances and the occurrence of major cardiovascular events (MACE). All patients with HF completed self-administered questionnaires on sleepiness, fatigue, insomnia, quality of sleep, sleep patterns, anxiety and depressive symptoms, and central nervous system (CNS) drugs intake. Patients were followed for a median of 888 days. Cox models were used to estimate the risk of MACE associated with baseline sleep characteristics. After adjustment for age, the risk of a future MACE increased with CNS drugs intake, sleep quality and insomnia scores as well with increased sleep latency, decreased sleep efficiency and total sleep time. However, after adjustment for left ventricular ejection fraction and hypercholesterolemia the HR failed to be significant except for CNS drugs and total sleep time. CNS drugs intake and decreased total sleep time were independently associated with an increased risk of MACE in patients with HF. Routine assessment of self-reported sleep disturbances should be considered to prevent the natural progression of HF.

**Keywords:** heart failure; sleep disturbances; sleep patterns; central nervous system drugs; sleep quality

## 1. Introduction

Heart failure (HF) is a common clinical syndrome characterized by inability of the ventricle to fill with or eject blood. HF is a major public health problem with a constantly increasing prevalence [1], a loss of quality of life, and a high mortality rate [2]. Major adverse cardiac events (MACE) are frequent in the history of HF and often lead to hospitalization which is an important marker for poor prognosis [3].

Patients with HF often have several non-cardiac comorbidities which are associated with an impaired quality of life and a poorer prognosis [4]. Identifying and treating the factors contributing to the progression of HF are therefore essential goals for an optimized management. Sleep disturbances are frequent with 60–75% of patients with HF complaining of poor sleep quality, more than 50% of insomnia [5,6] and 35% using regularly hypnotics [7]. The frequency of restless legs syndrome (RLS) varies between 4% and 40% depending on the studies [8,9]. Sleep-disordered breathing are also common (25–66%) in HF patients [10]. The natures and causes of sleep disorders are numerous and often associated in patients with HF, together with the potential for side effects of CNS drugs [11]. Patients with HF

<footnote n="1">¹ PhyMedExp, INSERM, CNRS, CHRU, University of Montpellier, 34295 Montpellier, France; f-bughin@chu-montpellier.fr (F.B.); b-ayoub@chu-montpellier.fr (B.A.); j-mercier@chu-montpellier.fr (J.M.)</footnote>

<footnote n="2">² INM, INSERM, Université de Montpellier, 34295 Montpellier, France; isabelle.jaussent@inserm.fr</footnote>

<footnote n="3">³ Cardiology Department, CHU de Montpellier, 34295 Montpellier, France; s-aguilhon@chu-montpellier.fr (S.A.); s-soltani@chu-montpellier.fr (S.S.)</footnote>

<footnote n="4">⁴ Clinical Pharmacy Department, CHU de Montpellier, University of Montpellier, 34295 Montpellier, France; n-chapet@chu-montpellier.fr</footnote>

<footnote n="5">⁵ Unité du Sommeil, Service de Neurologie, Centre National de Référence pour la Narcolepsie, CHU Montpellier, Hôpital Gui-de-Chauliac, 34295 Montpellier, France; y-dauvilliers@chu-montpellier.fr</footnote>

<footnote>* Correspondence: f-roubille@chu-montpellier.fr</footnote>
and poor sleep quality have increased deterioration in quality of life, alertness, and mood with a higher level of depressive symptoms [12]. A greater morbidity and mortality is also observed in patients with HF and poor quality sleep [12], sleep breathing disorders [13] or taking benzodiazepines [6]. However, most of these studies were limited by short-term follow-up or the use of simple questions instead of validated questionnaires to assess sleep disturbances in this population.

Based on the previous reported studies, we hypothesized that sleep disturbances are linked to a poorer long-term cardiovascular prognosis in patients with HF. Here we aimed to evaluate the association between baseline self-reported sleep characteristics using a comprehensive battery of validated questionnaires and CNS drug intake in 119 patients with HF over a period of 888 days.

## 2. Materials and Methods

### 2.1. Study Design and Population

This study was a longitudinal study on the occurrence of non-fatal and fatal MACE in patients with HF. All participants were admitted to the Cardiology Department, University Hospital Center of Montpellier. The study was approved by the local ethics committee (Institutional Review Board, Montpellier University Hospital, IRB-MTP_2020_05_202000496) (ClinicalTrials.gov identifier NCT04653883).

Among a population of almost 300 patients with HF, 119 patients (median age of 69 years (range = 44–89), 29.41% of women) were included with completed data of the questionnaire. These patients were followed in the Cardiology Department of the Montpellier University Hospital and diagnosed with HF according to the 2016 criteria of the European Society of Cardiology [14]. All patients filled in the questionnaires upon admission to a cardiology day hospital or outpatient clinic.

Patients were recruited between October 2016 and February 2020 and were followed up to the first non-fatal cardiovascular event, death or were censored on 1 March 2020, whichever came first.

### 2.2. Measures

Cardiac pathology, treatment and clinical data were collected on the patient's computerized medical record by the physicians. The cardiovascular and CNS drugs assessments were carried out by patients and physicians.

A self-administered questionnaire on sleep habits was completed by all patients in order to collect bedtime, waketime, sleep latency, total sleep time (TST), and sleep efficiency (i.e., ratio of the TST compared to the time in bed). RLS was defined using the International RLS Study Group (IRLSSG) criteria. Standardized questions addressed the presence of the four minimal diagnostic criteria of the IRLSSG: (1) Do you feel or have you ever felt an irresistible urge to move your legs? (2) If you feel or you have ever felt an irresistible urge to move your legs, does it begin or become worse during periods of rest or inactivity, such as sitting or lying down? (3) If you feel or you have ever felt an irresistible urge to move your legs, does it improve, at least partially, by movements such as walking or stretching your legs? (4) If you feel or you have ever felt an irresistible urge to move your legs, does it begin or become worse during the evening or the night? A positive answer to all four questions was required for a presumed diagnosis of RLS [15].

All patients also completed the following standardised questionnaires:

#### 1. Pittsburgh Sleep Quality Index—PSQI [16]

This questionnaire evaluates the quality of the patient's sleep during the last month before the visit. It is composed of 19 questions concerning 7 items, each item being scored between 0 and 3. The global score therefore varies from 0 to 21 and a high score corresponds to poor quality sleep. A score greater than or equal to 5 defines poor quality sleep.
## 2. Epworth Sleepiness Scale-ESS [17]

This questionnaire assesses excessive daytime sleepiness (EDS) through 8 different items or situations common or frequently found in everyday life during which the propensity to fall asleep or sleepiness is measured on a scale from 0 to 3. The score is noted from 0 to 24. A score of >10 defines the presence of excessive daytime sleepiness

## 3. Chalder Fatigue scale [18]

The 11-item Chalder fatigue scale is divided into two components: one that measures physical fatigue (7 questions) and one that measures mental fatigue (4 questions). A global binary fatigue score of 3 or less represents scores of those who are not fatigued, with scores of 4 or more equating to severe fatigue.

## 4. Insomnia Severity Scale-ISI [19]

This questionnaire estimates the severity of insomnia symptoms over the past month. It includes seven items scored between 0 and 4 with a total score between 0 and 28. The severity of insomnia symptoms is a function of the total score: not clinically significant between 0 and 7, mild between 8 and 14, moderate between 15 and 21 and severe between 22 and 28.

## 5. Beck Depression Inventory-BDI [20]

This 21-item questionnaire describes the patient's mood over the 2 weeks preceding the visit. Each item is scored from 0 to 3 with a total score between 0 and 63. A score between 10 and 18 indicates minor depression, 19 and 29 moderate depression, 30 and 63 severe depression.

## 6. Berlin Questionnaire [21]

This questionnaire is designed to identify people at risk of OSA. The questionnaire is self-administered and consists of 10 questions in three categories related to the presence and severity of snoring, frequency of daytime sleepiness, and the presence of obesity or hypertension. Patients have a 'high risk' of OSA if there are 2 or more categories where the score is positive.

## 2.3. CVD Outcome

Occurrence of MACE included death, hospitalization for heart failure, unplanned revascularization, heart transplantation and implantation of a defibrillator or circulatory assistance.

Mortality data were obtained from the public database of INSEE (Institut national de la statistique et des études économiques). Morbidity data were collected from computerized medical record data. These data were verified by the physicians in charge of these patients.

## 2.4. Statistical Analysis

Participants' characteristics are presented as median (minimum value; maximum value) for continuous variables, or number and percentages for categorical variables.

Cox proportional hazard models with delayed entry and age of the patients as the time scale were used to estimate hazard ratios (HR) and their CI. Demographic and clinical characteristics associated with risk of future MACE at *p* < 0.05 were included in Cox proportional hazard models to estimate the HR for the relationships between each sleep and mood characteristics and risk of future MACE. In the case of multiple events during follow-up, the first event was considered in the survival analysis. Two multivariate models were successively performed: (1) adjustment for left ventricular ejection fraction (LVEF), and hypercholesterolemia and (2) further adjustment for CNS drugs. When appropriate, the interaction terms were tested using the Wald-x2 test. The log-rank test was used to compare the Kaplan-Meier estimate curves for cardia-event free survival with events being right-censored.
Association between baseline characteristics and CNS drugs intake were compared using the Chi-square and Mann-Whitney U tests. Significance level was set at *p* < 0.05. Analyses were performed using SAS statistical software (version 9.4 SAS Inc., Cary, NC, USA).

### 3. Results

Among the 119 patients, respectively 60.50%, 50.00% and 36.75% had hypercholesterolemia, hypertension and diabetes and 28.21% were obese. (Table 1). A HF with reduced ejection fraction (HFrEF) was diagnosed for 46% of the patients. The primary cause of heart failure was ischemic heart disease in 57% of patients. A total 60.50% of patients used angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), 61.34% beta-blockers and 62.18% diuretics. Further, 24.37% took these 3 drugs together.

<table><caption>**Table 1.** Demographic and clinical characteristics of patients according to the occurrence of a CV event during the follow-up.</caption><thead><tr><th rowspan="3">Variable</th><th colspan="2">Whole Sample</th><th colspan="4">Occurrence of CV Events</th><th rowspan="3">HR (95% CI)</th><th rowspan="3">p</th></tr><tr><th colspan="2">n = 119</th><th colspan="2">No<br>n = 82</th><th colspan="2">Yes<br>n = 37</th><th rowspan="2">Model 0</th></tr><tr><th>n</th><th>%</th><th>n</th><th>%</th><th>n</th><th>%</th></tr></thead><tbody><tr><td>Sex, Female %</td><td>35</td><td>29.41</td><td>25</td><td>30.49</td><td>10</td><td>27.03</td><td>0.79 (0.38; 1.64)</td><td>0.531</td></tr><tr><td>BMI, kg/m²<sup>a</sup></td><td>117; 26.56<br>(18.21; 50.24)</td><td></td><td>81; 26.17<br>(18.21; 50.24)</td><td></td><td>36; 27.43<br>(18.36; 49.44)</td><td></td><td>1.03 (0.97; 1.09)</td><td>0.352</td></tr><tr><td>LVEF, %<sup>a</sup><br>HR for 10% increase</td><td>116; 40.00<br>(15.00; 70.00)</td><td></td><td>79; 43.00<br>(18.00; 70.00)</td><td></td><td>37; 30.00<br>(15.00; 60.00)</td><td></td><td>0.74 (0.57; 0.96)</td><td>0.021 *</td></tr><tr><td>Hypertension, Yes</td><td>59</td><td>50.00</td><td>39</td><td>48.15</td><td>20</td><td>54.05</td><td>1.08 (0.57; 2.07)</td><td>0.807</td></tr><tr><td>Diabetes mellitus, Yes</td><td>43</td><td>36.75</td><td>26</td><td>32.10</td><td>17</td><td>47.22</td><td>1.60 (0.83; 3.09)</td><td>0.159</td></tr><tr><td>Hypercholesterolemia, Yes</td><td>72</td><td>60.50</td><td>43</td><td>52.44</td><td>29</td><td>78.38</td><td>2.79 (1.28; 6.11)</td><td>0.010 *</td></tr><tr><td>Current smoker, Yes</td><td>43</td><td>36.44</td><td>33</td><td>40.74</td><td>10</td><td>27.03</td><td>0.57 (0.28; 1.19)</td><td>0.133</td></tr><tr><td>BDI-score total<sup>a</sup></td><td>112; 10.50<br>(0.00; 39.00)</td><td></td><td>77; 9.00<br>(0.00; 38.00)</td><td></td><td>35; 13.00<br>(3.00; 39.00)</td><td></td><td>1.03 (0.99; 1.06)</td><td>0.139</td></tr><tr><td>CFS—Total score<sup>a</sup></td><td>115; 8.00<br>(0.00; 14.00)</td><td></td><td>80; 7.00<br>(0.00; 14.00)</td><td></td><td>35; 9.00<br>(2.00; 14.00)</td><td></td><td>1.09 (0.99; 1.20)</td><td>0.078</td></tr></tbody></table>

At baseline, 63.46% complained of poor sleep quality, 21% reported moderate to severe insomnia symptoms, 28.70% an excessive daytime sleepiness and 10.81% had both insomnia symptoms and EDS. RLS was diagnosed in 5.56% of the patients. 35.09% of patients were at high risk for OSA. Around 30% were short sleeper (<7 h/night), 18% long sleeper (≥9 h/night) and 46% reported a sleep efficiency < 85%. Overall, 36 patients (30%) took central nervous system (CNS) drugs (benzodiazepines, Z-drugs (zolpidem and zopiclone) and antidepressant) (Table 2).

Over a median of 888 days follow-up (5–1470), 37 (31.09%) future MACE were observed, including 21 (17.65%) fatal events, 14 (11.76%) acute cardiac failure and 2 (0.02%) cardiac transplantation.

Each baseline socio-demographic and clinical characteristics of the patients according to the occurrence of MACE events during the follow-up are given in Table 1. The risk of future MACE increased in patients with a lower level of LVEF and with more hypercholesterolemia and in patients taking diuretics. We did not include this parameter in the multivariate model given a risk of overfitting (i.e., diuretics intake was associated with a lower LVEF, 35.00 (15.00–67.00) vs. 43.00 (20.00–70.00), *p* < 0.01).

<footnote>* Significant value, <sup>a</sup> continuous variables were expressed as number, median (minimal value; maximal value). Model 0: adjusted for age (timescale). Abbreviations: ACEI = angiotensin-converting enzyme inhibitors; ARA = angiotensin II receptor antagonists; BMI = body mass index; OSA = obstructive sleep apnea; BDI = Beck depression inventory; CFS = Chalder fatigue scale; LVEF = left ventricular ejection fraction.</footnote>
<table><caption>**Table 2.** Self-reported sleep parameters and central nervous system (CNS) drugs intake in patients as function of the occurrence of CV events during the follow-up.</caption><thead><tr><th rowspan="3">Variable</th><th colspan="2">Whole Sample</th><th colspan="4">Occurrence of CV Events</th><th colspan="2">Model 0</th><th colspan="2">Model 1</th><th colspan="2">Model 2</th></tr><tr><th rowspan="2">n</th><th rowspan="2">%</th><th colspan="2">No<br>n = 82</th><th colspan="2">Yes<br>n = 37</th><th rowspan="2">HR<br>(95% CI)</th><th rowspan="2">p</th><th rowspan="2">HR<br>(95% CI)</th><th rowspan="2">p</th><th rowspan="2">HR<br>(95% CI)</th><th rowspan="2">p</th></tr><tr><th>n</th><th>%</th><th>n</th><th>%</th></tr></thead><tbody><tr><td>CNS drugs, Yes</td><td>36</td><td>30.25</td><td>17</td><td>20.73</td><td>19</td><td>51.35</td><td>3.03 (1.59;<br>5.79)</td><td>&lt;0.001 *</td><td>2.37<br>(1.22;4.59)</td><td>0.010 *</td><td></td><td></td></tr><tr><td>ESS score <sup>a</sup></td><td>115; 7.00<br>(0.00; 22.00)</td><td></td><td>80; 6.00<br>(0.00; 22.00)</td><td></td><td>35; 9.00<br>(0.00; 22.00)</td><td></td><td>1.03<br>(0.97;1.09)</td><td>0.303</td><td>1.04 (0.98;<br>1.11)</td><td>0.187</td><td>1.04 (0.98;<br>1.11)</td><td>0.234</td></tr><tr><td>ESS score, &gt;10</td><td>33</td><td>28.70</td><td>21</td><td>26.25</td><td>12</td><td>34.29</td><td>1.31 (0.65;<br>2.64)</td><td>0.448</td><td>1.62 (0.80;<br>3.27)</td><td>0.178</td><td>1.45 (0.71;<br>2.93)</td><td>0.307</td></tr><tr><td>ISI score <sup>a</sup></td><td>115;<br>8.00 (0.00;<br>28.00)</td><td></td><td>79; 7.00<br>(0.00; 21.00)</td><td></td><td>36; 11.00<br>(1.00; 28.00)</td><td></td><td>1.07 (1.01;<br>1.12)</td><td>0.012 *</td><td>1.05 (1.00;<br>1.10)</td><td>0.048 *</td><td>1.03 (0.98;<br>1.09)</td><td>0.197</td></tr><tr><td>ISI score, &gt;14</td><td>24</td><td>20.87</td><td>14</td><td>17.72</td><td>10</td><td>27.78</td><td>1.52 (0.73;<br>3.15)</td><td>0.261</td><td>1.22 (0.58;<br>2.56)</td><td>0.593</td><td>0.96 (0.45;<br>2.07)</td><td>0.921</td></tr><tr><td>BQ score, ≥2</td><td>40</td><td>35.09</td><td>25</td><td>32.05</td><td>15</td><td>41.67</td><td>1.29 (0.67;<br>2.51)</td><td>0.449</td><td>1.41 (0.72;<br>2.74)</td><td>0.313</td><td>1.05 (0.51;<br>2.13)</td><td>0.903</td></tr><tr><td>RLS, ≥4</td><td>6</td><td>5.56</td><td>4</td><td>5.56</td><td>2</td><td>5.56</td><td>1.20 (0.29;<br>5.03)</td><td>0.798</td><td>1.22 (0.29;<br>5.09)</td><td>0.785</td><td>1.43 (0.34;<br>6.03)</td><td>0.630</td></tr><tr><td>PSQI score <sup>a</sup></td><td>104; 6.00<br>(0.00; 16.00)</td><td></td><td>71; 6.00<br>(0.00; 14.00)</td><td></td><td>33; 7.00<br>(1.00; 16.00)</td><td></td><td>1.10 (1.01;<br>1.20)</td><td>0.028 *</td><td>1.09 (1.00;<br>1.19)</td><td>0.059</td><td>1.05 (0.95;<br>1.15)</td><td>0.362</td></tr><tr><td>PSQI score, ≥5</td><td>66</td><td>63.46</td><td>42</td><td>59.15</td><td>24</td><td>72.73</td><td>1.29 (0.67;<br>2.51)</td><td>0.268</td><td>1.31 (0.60;<br>2.84)</td><td>0.496</td><td>0.94 (0.40;<br>2.18)</td><td>0.882</td></tr><tr><td>Sleep latency, min <sup>a</sup><br>HR For 15 min<br>Increase</td><td>117; 15.00<br>(0.00; 150.00)</td><td></td><td>80; 15.00<br>(0.00; 150.00)</td><td></td><td>37; 30.00<br>(0.00; 90.00)</td><td></td><td>1.11 (0.97;<br>1.28)</td><td>0.127</td><td>1.09 (0.94;<br>1.25)</td><td>0.255</td><td>1.10 (0.95;<br>1.28)</td><td>0.201</td></tr><tr><td>Sleep latency, min</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&lt;30</td><td>70</td><td>59.83</td><td>54</td><td>67.50</td><td>16</td><td>43.24</td><td>1</td><td>0.033 *</td><td>1</td><td>0.091</td><td>1</td><td>0.071</td></tr><tr><td>(30–60)</td><td>25</td><td>21.37</td><td>16</td><td>20.00</td><td>9</td><td>24.32</td><td>1.54 (0.68;<br>3.48)</td><td></td><td>1.47 (0.65;<br>3.36)</td><td></td><td>1.13 (0.48;<br>2.65)</td><td></td></tr><tr><td>&gt;60</td><td>22</td><td>18.80</td><td>10</td><td>12.50</td><td>12</td><td>32.43</td><td>2.72 (1.28;<br>5.74)</td><td></td><td>2.34 (1.09;<br>5.01)</td><td></td><td>2.38 (1.10;<br>5.14)</td><td></td></tr><tr><td>TST, hour <sup>a</sup><br>HR For 1 h decrease</td><td>119; 7:30<br>(3:00; 11:45)</td><td></td><td>82; 7:52<br>(3:00; 12:00)</td><td></td><td>37; 7:00<br>(3:15; 10:15)</td><td></td><td>0.79 (0.65;<br>0.98)</td><td>0.030 *</td><td>0.79<br>(0.64;<br>0.97)</td><td>0.037 *</td><td>0.81<br>(0.65;<br>1.01)</td><td>0.092</td></tr><tr><td>TST, ≤7 h</td><td>57</td><td>47.90</td><td>34</td><td>41.46</td><td>23</td><td>62.16</td><td>1.84 (0.95;<br>3.58)</td><td>0.072</td><td>1.72 (0.88;<br>3.36)</td><td>0.111</td><td>1.41 (0.70;<br>2.84)</td><td>0.333</td></tr><tr><td>Efficiency, % <sup>a</sup><br>HR for 10% increase</td><td>118; 87.50<br>(35.29; 100.00)</td><td></td><td>81; 88.57<br>(35.29; 100.00)</td><td></td><td>37; 82.35<br>(38.24;<br>100.00)</td><td></td><td>0.79 (0.65;<br>0.97)</td><td>0.022 *</td><td>0.85 (0.69;<br>1.05)</td><td>0.135</td><td>0.99 (0.97;<br>1.01)</td><td>0.353</td></tr><tr><td>Efficiency ≥85%</td><td>63</td><td>53.39</td><td>45</td><td>55.56</td><td>18</td><td>48.65</td><td>0.82 (0.43;<br>1.57)</td><td>0.551</td><td>1.02 (0.53;<br>1.97)</td><td>0.947</td><td>1.31 (0.66;<br>2.62)</td><td>0.440</td></tr></tbody></table>

### Association between Sleep Parameters, Mood Disturbances, CNS Drugs Intake and Future MACE

Baseline sleep parameters, mood disturbances and CNS drugs intake as a function of MACE events occurrence during the follow-up are given in Table 2. After adjustment for age, the risk of a future MACE increased with CNS drugs intake, PSQI and ISI scores as well as increased sleep latency and decreased sleep efficiency. We also found an increased occurrence of fatal and non-fatal MACE when total sleep time was reduced by one hour.

<footnote>* Significant value. <sup>a</sup> Continuous variables were expressed as number, median (minimal value; maximal value). Model 0: adjusted for age (timescale), Model 1: adjusted for age (timescale), left. Ventricular ejection fraction (%) and hypercholesterolemia. Model 2: adjusted for covariates in Model 1 plus CNS drugs intake. Abbreviations: BQ = Berlin questionnaire, ESS = Epworth severity scale, HR = hazard ratio, ISI = insomnia severity index, PSQI = Pittsburgh sleep quality index. TST = total sleep time, RLS = restless legs syndrome.</footnote>
When potential confounders were entered into the model (Model 1, Table 2), the HR were reduced and failed to be significant except for CNS drugs and total sleep time. Similar trends were found however for ISI and PSQI scores. When further adjusting for CNS drugs, the associations became not significant (Model 2, Table 2).

No interaction was found for future MACE event between CNS drugs intake and sleep disturbances.

Patients with HF who were taking CNS drugs had a lower LVEF (p = 0.02) and more hypercholesterolemia (p = 0.03). Moreover, they received worse scores for BDI (p < 0.01), ISI (p = 0.02), PSQI (p < 0.01) and fatigue dimension of Chalder fatigue scale (p = 0.02). Finally, these patients had a lower sleep efficiency (p = 0.04).

The Kaplan-Meier survival curves showed that cardiac event-free survival differed in patients who took CNS drugs vs. not (p = 0.001) (Figure 1).

<figure><img src="image_5.png" /><figcaption>Figure 1. Survival curve of patients with HF according to CNS drugs intake; MACE events.</figcaption></figure>

## 4. Discussion

Our study reported that sleep disturbances and CNS drugs intake are associated with a poor prognosis in patients with HF with long term follow-up.

This study emphasizes the importance of a detailed drug history in the population of HF patients. Indeed, the main finding of this study was the higher risk of MACE in patients who were taking CNS drugs. CNS drugs include benzodiazepines, Z-drugs and antidepressants (AD). We have chosen to bring these drugs together in a single entity given that their intake is often combined and their respective effects on the CNS are difficult to differentiate. While the relationship between hypnotic use and long-term mortality is not well established in the general population [22] a recent study found that the use of benzodiazepines was an independent predictor of rehospitalisation for HF patients [6]. The poorer prognosis of patients taking these drugs could be related to their potential side effects such as cognitive decline, daytime sleepiness, impairment in psychomotor performance [23] or respiratory depression [24]. The numerous comorbidities associated with the use of CNS drugs [22] and with patients with HF as confirmed in the present study could increase the risk of mortality and cardiovascular morbidity.

We also found an increased occurrence of fatal and non-fatal MACE when total sleep time was reduced by one hour. Short sleep duration (<7 h) is frequently found in the general population [25] and is associated with all-cause mortality [26] although this link is
not found in all studies [27]. Moreover, self-reported short sleep (<6 h) is associated with
high risk of developing HF in men with cardiovascular disease [28].

In unadjusted analysis, high sleep latency, poor sleep efficiency, poor sleep quality and insomnia symptoms severity were associated with a poorer prognosis in patients with HF. Sleep latency and sleep efficiency are good indicators of sleep quality [29] and should be evaluated to characterize the sleep of patients with HF. Our results were consistent with previous studies for total sleep time [30] and sleep quality [12,28,31]. However, several important differences exist between these studies and ours. First, these studies were secondary analyses, with no primary objective of exploring sleep problems in patients with HF. Secondly, the sleep assessment was often carried out with a single item or a single questionnaire, and never with a comprehensive battery of sleep questionnaires [12].

We did not find any significant results with factors frequently associated with an increased cardiovascular risk. First, sleepiness is a factor of severity in the presence of sleep breathing disorders and is associated with mortality and CVD morbidity [32,33] but it does not appear to be linked to the prognosis of heart failure patients in this study. We did not find any association with the presence of restless legs syndrome, although studies have shown an increase in mortality due to CVD associated or not with periodic leg movements [34–36].

There are some limitations in this study. The assessment of sleep parameters was only self-reported causing possible recall bias and a lack of accuracy in responses. However, we used validated questionnaires, which are simple tools that can be used by a large number of practitioners, to assess for sleepiness, fatigue, insomnia symptoms, RLS, proxy of OSA, quality of sleep, anxiety and depressive symptoms. In contrast, the presence of sleep apnea was not evaluated objectively, as no polysomnography was available for this specific study, and the Berlin questionnaire is not very specific in patients with cardiovascular diseases [37]. Finally, the use of diuretics was associated with the occurrence of MACE in univariate analysis, but we did not include this parameter in the multivariate model, because of the risk of overfitting. Indeed, LVEF was closely linked to the use of cardiological drugs with a lower LVEF in patients taking diuretics or beta blockers. Diuretics are used to control symptoms in patients with HF, especially fluid overload, but without effect on mortality [38]. Moreover, approximately 80% of patients with HF are taking diuretics with frequent changes in dosage [39], which makes their integration in the multivariate model irrelevant.

**5. Conclusions**

Our findings suggest that CNS drugs intake and decreased total sleep time were associated with an increased risk of fatal and non-fatal MACE in patients with HF. These results emphasize the importance of routinely screening for sleep symptoms and CNS drugs intake, especially in patients with severe HF to propose a specific management to improve the quality of life and prevent the natural progression of HF.

**Author Contributions:** F.B.: drafting/revising the manuscript for content, including medical writing for content; interpretation of data analysis; acquisition of data. I.J.: performing statistical analysis; interpretation of data analysis; revising the manuscript for content. F.R. and Y.D.: drafting/revising the manuscript for content, including medical writing for content; study concept or design; interpretation of data analysis, study supervision and coordination. B.A. and S.S.: data curation. S.A.: investigation. J.M.: revising the manuscript for content. N.C.: data curation. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was approved by the local ethics committee (Institutional Review Board, Montpellier University Hospital) (ClinicalTrials.gov identifier NCT04653883).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Data would be provided under reasonable request.
**Acknowledgments:** The authors gratefully acknowledge S. Kahlouche and E Devroedt for their help in collecting data.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Groenewegen, A.; Rutten, F.H.; Mosterd, A.; Hoes, A.W. Epidemiology of heart failure. *Eur. J. Heart Fail.* **2020**, *22*, 1342–1356.
[CrossRef]

2. Shah, K.S.; Xu, H.; Matsouaka, R.A.; Bhatt, D.L.; Heidenreich, P.A.; Hernandez, A.F.; Devore, A.D.; Yancy, C.W.; Fonarow, G.C. Heart failure with preserved, borderline, and reduced ejection fraction: 5-Year outcomes. *J. Am. Coll. Cardiol.* **2017**, *70*, 2476–2486.
[CrossRef]

3. Malik, A.; Gill, G.S.; Lodhi, F.K.; Tummala, L.S.; Singh, S.N.; Morgan, C.J.; Allman, R.M.; Fonarow, G.C.; Ahmed, A. Prior heart failure hospitalization and outcomes in patients with heart failure with preserved and reduced ejection fraction. *Am. J. Med.* **2020**, *133*, 84–94.
[CrossRef]

4. Bhatt, A.S.; Ambrosy, A.P.; Dunning, A.; DeVore, A.D.; Butler, J.; Reed, S.; Voors, A.; Starling, R.; Armstrong, P.W.; Ezekowitz, J.A.; et al. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial-insights from ASCEND-HF. *Eur. J. Heart Fail.* **2020**, *22*, 1022–1031.
[CrossRef] [PubMed]

5. Kanno, Y.; Yoshihisa, A.; Watanabe, S.; Takiguchi, M.; Yokokawa, T.; Sato, A.; Miura, S.; Shimizu, T.; Nakamura, Y.; Abe, S.; et al. Prognostic significance of insomnia in heart failure. *Circ. J.* **2016**, *80*, 1571–1577.
[CrossRef] [PubMed]

6. Sato, Y.; Yoshihisa, A.; Hotsuki, Y.; Watanabe, K.; Kimishima, Y.; Kiko, T.; Kanno, Y.; Yokokawa, T.; Abe, S.; Misaka, T.; et al. Associations of benzodiazepine with adverse prognosis in heart failure patients with insomnia. *J. Am. Heart Assoc.* **2020**, *9*, e013982.
[CrossRef]

7. Jorge-Samitier, P.; Durante, A.; Gea-Caballero, V.; Antón-Solanas, I.; Fernández-Rodrigo, M.T.; Juárez-Vela, R. Sleep quality in patients with heart failure in the spanish population: A cross-sectional study. *Int. J. Environ. Res. Public Health* **2020**, *17*, 7772.
[CrossRef]

8. Zilberman, M.; Silverberg, D.S.; Schwartz, D.; Oksenberg, A. Restless legs syndrome (RLS) in anemic patients with congestive heart failure and chronic renal failure: Lack of effect of anemia treatment. *Int. J. Cardiol.* **2010**, *143*, 205–207.
[CrossRef] [PubMed]

9. Príncipe-Rodríguez, K.; Strohl, K.P.; Hadziefendic, S.; Piña, I.L. Sleep symptoms and clinical markers of illness in patients with heart failure. *Sleep Breath.* **2005**, *9*, 127–133.
[CrossRef]

10. Javaheri, S.; Barbe, F.; Campos-Rodriguez, F.; Dempsey, J.A.; Khayat, R.; Javaheri, S.; Malhotra, A.; Martinez-Garcia, M.A.; Mehra, R.; Pack, A.I.; et al. Types, mechanisms, and clinical cardiovascular consequences. *J. Am. Coll. Cardiol.* **2017**, *69*, 841–858.
[CrossRef] [PubMed]

11. Zuurbier, L.A.; Luik, A.I.; Leening, M.J.G.; Hofman, A.; Freak-Poli, R.; Franco, O.H.; Stricker, B.H.; Tiemeier, H. Associations of heart failure with sleep quality: The Rotterdam Study. *J. Clin. Sleep Med. JCSM Off. Publ. Am. Acad. Sleep Med.* **2015**, *11*, 117–121.
[CrossRef]

12. Lee, K.S.; Lennie, T.A.; Heo, S.; Song, E.K.; Moser, D.K. Prognostic importance of sleep quality in patients with heart failure. *Am. J. Crit. Care Off. Publ. Am. Assoc. Crit. Care Nurs.* **2016**, *25*, 516–525.
[CrossRef] [PubMed]

13. Damy, T.; Margarit, L.; Noroc, A.; Bodez, D.; Guendouz, S.; Boyer, L.; Drouot, X.; Lamine, A.; Paulino, A.; Rappeneau, S.; et al. Prognostic impact of sleep-disordered breathing and its treatment with nocturnal ventilation for chronic heart failure. *Eur. J. Heart Fail.* **2012**, *14*, 1009–1019.
[CrossRef] [PubMed]

14. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.-P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur. J. Heart Fail.* **2016**, *18*, 891–975.
[PubMed]

15. Allen, R.P.; Picchietti, D.L.; Garcia-Borreguero, D.; Ondo, W.G.; Walters, A.S.; Winkelman, J.W.; Zucconi, M.; Ferri, R.; Trenkwalder, C.; Lee, H.B.; et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—History, rationale, description, and significance. *Sleep Med.* **2014**, *15*, 860–873.
[CrossRef]

16. Buysse, D.J.; Reynolds, C.F.; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. *Psychiatr. Res.* **1989**, *28*, 193–213.
[CrossRef]

17. Johns, M.W. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. *Sleep* **1991**, *14*, 540–545.
[CrossRef]

18. Cella, M.; Chalder, T. Measuring fatigue in clinical and community settings. *J. Psychosom. Res.* **2010**, *69*, 17–22.
[CrossRef]

19. Bastien, C.H.; Vallières, A.; Morin, C.M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med.* **2001**, *2*, 297–307.
[CrossRef]

20. Beck, A.T.; Steer, R.A.; Ball, R.; Ranieri, W. Comparison of beck depression inventories-IA and -II in psychiatric outpatients. *J. Pers. Assess.* **1996**, *67*, 588–597.
[CrossRef]

21. Netzer, N.C.; Stoohs, R.A.; Netzer, C.M.; Clark, K.; Strohl, K.P. Using the berlin questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann. Intern. Med.* **1999**, *131*, 485–491.
[CrossRef]

22. Jaussent, I.; Ancelin, M.-L.; Berr, C.; Pérès, K.; Scali, J.; Besset, A.; Ritchie, K.; Dauvilliers, Y. Hypnotics and mortality in an elderly general population: A 12-year prospective study. *BMC Med.* **2013**, *11*, 212.
[CrossRef]
23. Enomoto, M.; Kitamura, S.; Tachimori, H.; Takeshima, M.; Mishima, K. Long-term use of hypnotics: Analysis of trends and risk factors. *Gen. Hosp. Psychiatr.* **2020**, *62*, 49–55. [CrossRef]

24. Kang, M.; Galuska, M.A.; Ghassemzadeh, S. *Benzodiazepine Toxicity*; StatPearls Publishing: Treasure Island, FL, USA, 2021.

25. Depner, C.M.; Cheng, P.C.; Devine, J.K.; Khosla, S.; de Zambotti, M.; Robillard, R.; Vakulin, A.; Drummond, S.P.A. Wearable technologies for developing sleep and circadian biomarkers: A summary of workshop discussions. *Sleep* **2019**, *43*, zsz254. [CrossRef]

26. Yin, J.; Jin, X.; Shan, Z.; Li, S.; Huang, H.; Li, P.; Peng, X.; Peng, Z.; Yu, K.; Bao, W.; et al. Relationship of sleep duration with all-cause mortality and cardiovascular events: A systematic review and dose-response meta-analysis of prospective cohort studies. *J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis.* **2017**, *6*, e005947. [CrossRef]

27. Kwok, C.S.; Kontopantelis, E.; Kuligowski, G.; Gray, M.; Muhyaldeen, A.; Gale, C.P.; Peat, G.M.; Cleator, J.; Chew-Graham, C.; Loke, Y.K.; et al. Self-reported sleep duration and quality and cardiovascular disease and mortality: A dose-response meta-analysis. *J. Am. Heart Assoc.* **2018**, *7*, e008552. [CrossRef] [PubMed]

28. Wannamethee, S.G.; Papacosta, O.; Lennon, L.; Whincup, P.H. Self-reported sleep duration, napping, and incident heart failure: Prospective associations in the british regional heart study. *J. Am. Geriatr. Soc.* **2016**, *64*, 1845–1850. [CrossRef] [PubMed]

29. Ohayon, M.; Wickwire, E.M.; Hirshkowitz, M.; Albert, S.M.; Avidan, A.; Daly, F.J.; Dauvilliers, Y.; Ferri, R.; Fung, C.; Gozal, D.; et al. National sleep foundation's sleep quality recommendations: First report. *Sleep Health* **2017**, *3*, 6–19. [CrossRef]

30. Reinhard, W.; Plappert, N.; Zeman, F.; Hengstenberg, C.; Riegger, G.; Novack, V.; Maimon, N.; Pfeifer, M.; Arzt, M. Prognostic impact of sleep duration and sleep efficiency on mortality in patients with chronic heart failure. *Sleep Med.* **2013**, *14*, 502–509. [CrossRef]

31. Johansson, P.; Broström, A.; Sanderman, R.; Jaarsma, T. The course of sleep problems in patients with heart failure and associations to rehospitalizations. *J. Cardiovasc. Nurs.* **2015**, *30*, 403–410. [CrossRef] [PubMed]

32. Empana, J.-P.; Dauvilliers, Y.; Dartigues, J.-F.; Ritchie, K.; Gariepy, J.; Jouven, X.; Tzourio, C.; Amouyel, P.; Besset, A.; Ducimetiere, P. Excessive daytime sleepiness is an independent risk indicator for cardiovascular mortality in community-dwelling elderly: The three city study. *Stroke* **2009**, *40*, 1219–1224. [CrossRef]

33. Blachier, M.; Dauvilliers, Y.; Jaussent, I.; Helmer, C.; Ritchie, K.; Jouven, X.; Tzourio, C.; Amouyel, P.; Besset, A.; Ducimetiere, P.; et al. Excessive daytime sleepiness and vascular events: The Three city study. *Ann. Neurol.* **2012**, *71*, 661–667. [CrossRef]

34. Yoshihisa, A.; Suzuki, S.; Kanno, Y.; Takiguchi, M.; Sato, A.; Miura, S.; Masuda, A.; Yokokawa, T.; Shimizu, T.; Nakamura, Y.; et al. Prognostic significance of periodic leg movements during sleep in heart failure patients. *Int. J. Cardiol.* **2016**, *212*, 11–13. [CrossRef] [PubMed]

35. Li, Y.; Li, Y.; Winkelman, J.W.; Walters, A.S.; Han, J.; Hu, F.B.; Gao, X. Prospective study of restless legs syndrome and total and cardiovascular mortality among women. *Neurology* **2018**, *90*, e135–e141. [CrossRef] [PubMed]

36. Gao, X.; Ba, D.M.; Bagai, K.; Liu, G.; Ma, C.; Walters, A.S. Treating restless legs syndrome was associated with low risk of cardiovascular disease: A cohort study with 3.4 years of follow-up. *J. Am. Heart Assoc.* **2021**, *10*, e018674. [CrossRef] [PubMed]

37. Reuter, H.; Herkenrath, S.; Treml, M.; Halbach, M.; Steven, D.; Frank, K.; Castrogiovanni, A.; Kietzmann, I.; Baldus, S.; Randerath, W.J. Sleep-disordered breathing in patients with cardiovascular diseases cannot be detected by ESS, STOP-BANG, and Berlin questionnaires. *Clin. Res. Cardiol. Off. J. Geriatr. Cardiol. Soc.* **2018**, *107*, 1071–1078. [CrossRef]

38. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur. Heart J.* **2021**, *42*, 3599–3726. [CrossRef]

39. Kapelios, C.J.; Laroche, C.; Crespo-Leiro, M.G.; Anker, S.D.; Coats, A.J.S.; Díaz-Molina, B.; Filippatos, G.; Lainscak, M.; Maggioni, A.P.; McDonagh, T.; et al. Association between loop diuretic dose changes and outcomes in chronic heart failure: Observations from the ESC-EORP Heart Failure Long-Term Registry. *Eur. J. Heart Fail.* **2020**, *22*, 1424–1437. [CrossRef]